Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
Maiko Inoue, Akira Arakawa, Shin Yamane, Kazuaki Kadonosono Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan Background: The purpose of this study was to assess visual function and vision-related ­quality of life after intravitreal injection of ranibiz...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1c038f6f29ba4688a82846359c393481 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1c038f6f29ba4688a82846359c393481 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1c038f6f29ba4688a82846359c3934812021-12-02T00:11:30ZIntravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life1177-5483https://doaj.org/article/1c038f6f29ba4688a82846359c3934812014-09-01T00:00:00Zhttp://www.dovepress.com/intravitreal-injection-of-ranibizumab-using-anbsppro-re-nata-regimen-f-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Maiko Inoue, Akira Arakawa, Shin Yamane, Kazuaki Kadonosono Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan Background: The purpose of this study was to assess visual function and vision-related ­quality of life after intravitreal injection of ranibizumab (IVR) using a pro re nata regimen for the treatment of age-related macular degeneration.Methods: A prospective study of 54 eyes in 54 patients scheduled to undergo IVR for the treatment of exudative age-related macular degeneration was performed. A self-administered, 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was completed before and 3 and 12 months after the initial IVR treatment. We evaluated logMAR visual acuity and NEI VFQ-25 scores preoperatively and postoperatively. Further, associations between the changes in NEI VFQ-25 scores and patient characteristics were investigated at 12 months. Results: Postoperative best-corrected visual acuity improved significantly when compared with the preoperative visual acuity throughout the 12-month period (P<0.05 at 3 and 12 months, respectively). On the other hand, IVR treatment significantly improved the postoperative NEI VFQ-25 mean composite score at both 3 and 12 months (P<0.05, respectively). Better visual acuity at 12 months was associated with a greater improvement in NEI VFQ-25 score at 12 months (P<0.05). Conclusion: IVR was well tolerated and improved vision in these patients with age-related macular degeneration, as evaluated at one-year follow-up examinations. IVR also enabled good subjective perception, as indicated by higher composite NEI VFQ-25 scores. Maintaining good visual acuity may be an important factor for improving vision-related quality of life. Keywords: age-related macular degeneration, ranibizumab, intravitreal injection, vascular endothelial growth factor, vision-related quality of lifeInoue MArakawa AYamane SKadonosono KDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1711-1716 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Inoue M Arakawa A Yamane S Kadonosono K Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life |
| description |
Maiko Inoue, Akira Arakawa, Shin Yamane, Kazuaki Kadonosono Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan Background: The purpose of this study was to assess visual function and vision-related ­quality of life after intravitreal injection of ranibizumab (IVR) using a pro re nata regimen for the treatment of age-related macular degeneration.Methods: A prospective study of 54 eyes in 54 patients scheduled to undergo IVR for the treatment of exudative age-related macular degeneration was performed. A self-administered, 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was completed before and 3 and 12 months after the initial IVR treatment. We evaluated logMAR visual acuity and NEI VFQ-25 scores preoperatively and postoperatively. Further, associations between the changes in NEI VFQ-25 scores and patient characteristics were investigated at 12 months. Results: Postoperative best-corrected visual acuity improved significantly when compared with the preoperative visual acuity throughout the 12-month period (P<0.05 at 3 and 12 months, respectively). On the other hand, IVR treatment significantly improved the postoperative NEI VFQ-25 mean composite score at both 3 and 12 months (P<0.05, respectively). Better visual acuity at 12 months was associated with a greater improvement in NEI VFQ-25 score at 12 months (P<0.05). Conclusion: IVR was well tolerated and improved vision in these patients with age-related macular degeneration, as evaluated at one-year follow-up examinations. IVR also enabled good subjective perception, as indicated by higher composite NEI VFQ-25 scores. Maintaining good visual acuity may be an important factor for improving vision-related quality of life. Keywords: age-related macular degeneration, ranibizumab, intravitreal injection, vascular endothelial growth factor, vision-related quality of life |
| format |
article |
| author |
Inoue M Arakawa A Yamane S Kadonosono K |
| author_facet |
Inoue M Arakawa A Yamane S Kadonosono K |
| author_sort |
Inoue M |
| title |
Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life |
| title_short |
Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life |
| title_full |
Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life |
| title_fullStr |
Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life |
| title_full_unstemmed |
Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life |
| title_sort |
intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/1c038f6f29ba4688a82846359c393481 |
| work_keys_str_mv |
AT inouem intravitrealinjectionofranibizumabusinganbspprorenataregimenforagerelatedmaculardegenerationandvisionrelatedqualityoflife AT arakawaa intravitrealinjectionofranibizumabusinganbspprorenataregimenforagerelatedmaculardegenerationandvisionrelatedqualityoflife AT yamanes intravitrealinjectionofranibizumabusinganbspprorenataregimenforagerelatedmaculardegenerationandvisionrelatedqualityoflife AT kadonosonok intravitrealinjectionofranibizumabusinganbspprorenataregimenforagerelatedmaculardegenerationandvisionrelatedqualityoflife |
| _version_ |
1718403849902882816 |